| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/31/2011 | WO2011038283A1 Novel macrocyclic inhibitors of hepatitis c virus replication |
| 03/31/2011 | WO2011038278A2 Micelle encapsulation of therapeutic agents |
| 03/31/2011 | WO2011038261A1 Heterocyclic kinase inhibitors |
| 03/31/2011 | WO2011038234A2 Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions |
| 03/31/2011 | WO2011038224A1 Methods for treating viral disorders |
| 03/31/2011 | WO2011038210A2 Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
| 03/31/2011 | WO2011038207A1 Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| 03/31/2011 | WO2011038205A2 Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh |
| 03/31/2011 | WO2011038204A1 Novel dihydropyrimidin-2(1h)-one compounds as s-nitrosoglutathione reductase inhibitors |
| 03/31/2011 | WO2011038164A1 Bridged heterocyclic compounds and methods of use |
| 03/31/2011 | WO2011038163A1 Pyrido[3,4-b]indoles and methods of use |
| 03/31/2011 | WO2011038162A1 Pyrido(3,4-b)indoles and methods of use |
| 03/31/2011 | WO2011038161A1 Pyrido[4,3-b]indoles and methods of use |
| 03/31/2011 | WO2011038160A2 Compositions and methods for silencing genes expressed in cancer |
| 03/31/2011 | WO2011038159A2 Dr5 ligand drug conjugates |
| 03/31/2011 | WO2011038157A2 Zinc-containing compositions for the treatment of diseases, illnesses and syndromes associated with exposure to pore forming toxins |
| 03/31/2011 | WO2011038152A2 Toll-like receptor modulators and uses thereof |
| 03/31/2011 | WO2011038124A2 Systems and methods for treating depression, including the use of neurobehavioral tasks |
| 03/31/2011 | WO2011038120A1 Surface coatings for skin |
| 03/31/2011 | WO2011038097A2 Indolizine inhibitors of 5-lipoxygenase |
| 03/31/2011 | WO2011038086A2 Indolizine inhibitors of 5-lipoxygenase |
| 03/31/2011 | WO2011038085A1 Combination |
| 03/31/2011 | WO2011038082A1 Combination |
| 03/31/2011 | WO2011038064A2 Manufacture of tablet in a die utilizing powder blend containing water-containing material |
| 03/31/2011 | WO2011038047A1 Methods of treatment with a low molecular weight heparin composition |
| 03/31/2011 | WO2011038031A1 Dual targeting sirna agents |
| 03/31/2011 | WO2011038014A2 Composition and method for treatment of diabetes |
| 03/31/2011 | WO2011037962A1 Methods and pharmaceutical compositions for treating down syndrome |
| 03/31/2011 | WO2011037913A2 Methods for preventing oxidative stress injury of a tissue by a folate-tempol conjugate |
| 03/31/2011 | WO2011037912A1 Compositions and methods for inducing or enhancing connective tissue repair |
| 03/31/2011 | WO2011037833A2 Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| 03/31/2011 | WO2011037815A1 Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
| 03/31/2011 | WO2011037795A1 Compounds which selectively modulate the cb2 receptor |
| 03/31/2011 | WO2011037780A1 Imidothiazole kinase inhibitors |
| 03/31/2011 | WO2011037771A1 Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| 03/31/2011 | WO2011037731A1 Boron containing small molecules |
| 03/31/2011 | WO2011037644A1 Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy |
| 03/31/2011 | WO2011037613A1 Crystalline forms and processes for the preparation of pgi2 receptor agonists |
| 03/31/2011 | WO2011037610A1 Prostaglandin transporter inhibitors and uses thereof |
| 03/31/2011 | WO2011037495A1 Veterinary pharmaceutical composition and method (alternatives) for the prophylaxis and treatment of diseases of the gastrointestinal tract and intoxications of diverse etiology in animals |
| 03/31/2011 | WO2011037467A1 Atazanavir for treating inflammatory diseases |
| 03/31/2011 | WO2011037433A2 Use of a quinolone derivative containing 7-(4-aminomethyl-3-oxime)pyrrolidine group that is capable of inducing granulocyte colony stimulating factor for treatment of neutropenia and recovery of hematopoiesis |
| 03/31/2011 | WO2011037411A2 Composition comprising s-allyl-l-cysteine as active ingredient for preventing or treating gastrointestinal disorders |
| 03/31/2011 | WO2011037355A2 Pharmaceutical composition for treating and preventing diseases involving joints and connective tissue |
| 03/31/2011 | WO2011037281A1 Slow-release cilostazol tablet having an improved elution rate and minimal side effects |
| 03/31/2011 | WO2011037252A1 Liposome preparation containing spicamycin derivative |
| 03/31/2011 | WO2011037223A1 Agent for reducing visceral fat weight |
| 03/31/2011 | WO2011037192A1 Substituted amide compound |
| 03/31/2011 | WO2011037100A1 Prophylactic or therapeutic agent for gum disease or apical periodontitis |
| 03/31/2011 | WO2011037099A1 Composition comprising curcuma longa extract together with curcuma zedoaria extract |
| 03/31/2011 | WO2011037058A1 Lactase preparation |
| 03/31/2011 | WO2011037047A1 Melanin production inhibitor |
| 03/31/2011 | WO2011036904A1 Agent for preventing adverse side effects of carcinostatic agent |
| 03/31/2011 | WO2011036895A1 Maleic acid salt and crystal thereof |
| 03/31/2011 | WO2011036889A1 Heterocyclic compound |
| 03/31/2011 | WO2011036885A1 Heterocyclic compound |
| 03/31/2011 | WO2011036879A1 Transferrin liposome preparation |
| 03/31/2011 | WO2011036786A1 Stress-alleviating agent comprising plant-derived polyamine-containing extract as active ingredient |
| 03/31/2011 | WO2011036677A2 Sustained release composition of ranolazine |
| 03/31/2011 | WO2011036676A2 Stable cocrystals of temozolomide |
| 03/31/2011 | WO2011036651A1 Pyrazoline dione derivatives as nadph oxidase inhibitors |
| 03/31/2011 | WO2011036648A1 Polymorphs of sorafenib acid addition salts |
| 03/31/2011 | WO2011036599A1 A dissolvable film strip comprising natural components |
| 03/31/2011 | WO2011036576A1 Gpr 119 modulators |
| 03/31/2011 | WO2011036557A1 Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles |
| 03/31/2011 | WO2011036537A1 Hydroxytyrosol compounds |
| 03/31/2011 | WO2011036533A1 Pharmaceutical composition comprising prasugrel and triflusal |
| 03/31/2011 | WO2011036505A1 New 6-substituted pyrimidine derivatives |
| 03/31/2011 | WO2011036478A1 Piperidine and piperazine derivatives as smo antagonists |
| 03/31/2011 | WO2011036461A1 Fused imidazo [3, 2 - d] pyrazines as pi3 kinase inhibitors |
| 03/31/2011 | WO2011036400A1 Galenic form suitable for absorbing, in a specific manner, the undesirable molecules in the digestive tract |
| 03/31/2011 | WO2011036357A2 Stable, liquid, ready-to-use ketoprofen formulation |
| 03/31/2011 | WO2011036305A2 New use of pdgfrbeta inhibitors |
| 03/31/2011 | WO2011036303A1 New aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the met family |
| 03/31/2011 | WO2011036299A1 Irreversible inhibitors useful for the treatment of kinase-related pathologies |
| 03/31/2011 | WO2011036284A1 Benzoxepin pi3k inhibitor compounds and methods of use |
| 03/31/2011 | WO2011036280A1 Benzoxazepin pi3k inhibitor compounds and methods of use |
| 03/31/2011 | WO2011036265A1 N-acetyl-l-cysteine for the treatment of endometriosis |
| 03/31/2011 | WO2011036204A1 [1,4]-benzodiazepines as vasopressin v2 receptor antagonists |
| 03/31/2011 | WO2011036202A1 Retinal neuroprotection by ion channel blockers regulated by the sur subunit |
| 03/31/2011 | WO2011036167A1 Use of nicotinic acetylcholine receptor alpha 7 activators |
| 03/31/2011 | WO2011036159A2 Treatment and prevention of hiv infection |
| 03/31/2011 | WO2011036130A1 Indole derivatives as crac modulators |
| 03/31/2011 | WO2011036128A1 Heterocyclic antiviral compounds |
| 03/31/2011 | WO2011036127A1 Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors |
| 03/31/2011 | WO2011036114A1 Oral pharmaceutical composition comprising diclofenac |
| 03/31/2011 | WO2011036048A1 Disinfecting agent comprising eugenol, terpineol and thymol |
| 03/31/2011 | WO2011036047A1 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases |
| 03/31/2011 | WO2011035941A1 Lysine specific demethylase-1 inhibitors and their use |
| 03/31/2011 | WO2011035900A1 New thiadiazole derivatives |
| 03/31/2011 | WO2011035855A1 Pyridinyl-imidazolone derivatives for inhibiting pi3 kinases |
| 03/31/2011 | WO2011035829A1 Pharmaceutical compositions for treating dysregulated inflammatory diseases |
| 03/31/2011 | WO2011035540A1 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors |
| 03/31/2011 | WO2011035534A1 Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof |
| 03/31/2011 | WO2011035518A1 Pyrimidine derivatives and analogs, preparation method and use thereof |
| 03/31/2011 | WO2011035500A1 Use of piperphentonamine or salts thereof in manufacture of medicaments for preventing / treating brain diseases |
| 03/31/2011 | WO2011035434A1 Gallium complex anti microbial compounds, compositions, uses and methods |
| 03/31/2011 | WO2011035417A1 Hsp-90 binding compounds, compositions thereof, and their use fn the treatment of autoimmune and inflammatory diseases |
| 03/31/2011 | WO2011035416A1 Hsp90 modulating compounds, compositions, methods and uses |
| 03/31/2011 | WO2011035355A1 Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives |